复方丹参滴丸与阿司匹林用于血液透析患者冠心病的效果比较

发布时间：2018-07-12 18:53

本文选题：复方丹参滴丸 + 阿司匹林　；参考：《中华中医药杂志》2016年10期

【摘要】：目的:通过随机对照试验,比较合并冠心病的维持血液透析患者应用复方丹参滴丸或阿司匹林的临床获益与安全性。方法:纳入本单位合格受试者,随机入组复方丹参滴丸组或阿司匹林组,记录治疗前后人口学特征、透析相关参数、实验室检查指标,以及1年期间发生的死亡、心血管事件、住院事件、出血事件,比较两组之间上述指标的差异。结果:研究共筛查了213例维持性血液透析患者,按照纳入和排除标准,53例合格受试者随机入组复方丹参滴丸组(27例)和阿司匹林组(26例)。两组患者在基线资料方面未见统计学差异。观察期间,阿司匹林组有1名患者中途退出。两组患者终点事件的风险、出血事件发生风险比较无显著性差异。两组患者的住院事件发生频率无显著性差异。结论:对于合并冠心病的维持血液透析患者,可选择复方丹参滴丸或阿司匹林作为二级预防用药,二者对临床结局的影响作用相当。
[Abstract]:Objective: to compare the clinical benefits and safety of compound salvia miltiorrhiza drop pills or aspirin in maintenance hemodialysis patients with coronary heart disease by randomized controlled trial. Methods: the demographics, dialysation-related parameters, laboratory parameters, death and cardiovascular events occurred during one year were recorded in the eligible subjects of our unit and randomly in the compound salvia miltiorrhiza drop pill group or aspirin group. Hospitalization events and bleeding events were compared between the two groups. Results: a total of 213 maintenance hemodialysis patients were screened. According to the inclusion and exclusion criteria, 53 eligible subjects were randomly enrolled into the compound Danshen dripping pill group (27 cases) and aspirin group (26 cases). There was no statistical difference in baseline data between the two groups. During the observation period, one patient in the aspirin group quit midway. There was no significant difference in the risk of endpoint events and bleeding events between the two groups. There was no significant difference in the frequency of hospitalization events between the two groups. Conclusion: compound salvia miltiorrhiza drop pills or aspirin can be used as secondary preventive drugs for maintenance hemodialysis patients with coronary heart disease.
【作者单位】：广东省中医院透析科;柳州市中医院肾病科;
【基金】：广东省科技计划项目(No.2012B031800209)~~
【分类号】：R459.5;R541.4

【相似文献】